Evidence map›Paper›PMID 34221949›Full record

ReviewAnesthesiology and pain medicine2021

Topical Sevoflurane: A Novel Treatment for Chronic Pain Caused by Venous Stasis Ulcers.

Mayank Aranke, Cynthia T Pham, Melis Yilmaz, Jason K Wang, Vwaire Orhurhu, Daniel An, Elyse M Cornett, Alan David Kaye, Anh L Ngo, Farnad Imani and 4 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Anesthesiology and pain medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 3 countries.

Mayank ArankeTexas Tech University Health Sciences Center, School of Medicine, Harvard TH Chan School of Public Health, Lubbock, Texas, USA.
Cynthia T PhamGeorgetown University School of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.
Melis YilmazHarvard Medical School, Boston, MA, USA.
Jason K WangHarvard Medical School, Boston, MA, USA.
Vwaire OrhurhuMassachusetts General Hospital, Boston, MA, USA.
Daniel AnGeorgetown University School of Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.
Elyse M CornettLSU Health Shreveport, Department of Anesthesiology, Shreveport, LA, USA.
Alan David KayeLSU Health Shreveport, Department of Anesthesiology, Shreveport, LA, USA.
Anh L NgoPain Specialty Group, Portsmouth, NH, USA.
Farnad ImaniPain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-0814-0772
Reza Farahmand RadPain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-2783-6652
Giustino VarrassiPaolo Procacci Foundation, Via Tacito 7, Roma, Italy.ORCID https://orcid.org/0000-0002-3822-2923
Omar ViswanathLSU Health Shreveport, Department of Anesthesiology, Shreveport, LA, USA.ORCID https://orcid.org/0000-0002-6124-7037
Ivan UritsLSU Health Shreveport, Department of Anesthesiology, Shreveport, LA, USA.ORCID https://orcid.org/0000-0002-3652-6085
Georgetown University · USHarvard University · USIran University of Medical Sciences · IRLouisiana State University Health Sciences Center Shreveport · USChildren's Specialty Group · USCreighton University · USFondazione Roma · ITMassachusetts General Hospital · USSouthCoast Health · USTexas Tech University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the US, an estimated 1 - 2% of chronic venous insufficiency (CVI) patients (of 6 - 7 million nationwide) develop at least one venous stasis ulcer (VSU) during their illness. Of these, approximately 40% develop subsequent ulcers, making VSU prognostically poor. Current management of VSU is costly, with poor prognosis, high recurrence rate, inadequate pain management, and significantly reduced quality of life (QoL). Topical volatile anesthetic agents, such as sevoflurane, offer improved pain relief and symptom control in patients suffering from chronic VSU. The immediate impact of topical sevoflurane in reducing pain associated with ulcer bed debridement has several implications in improving the quality of life in patients with CVI induced ulcers and in the prognosis and healing of the ulcers. This review summarizes a topical formulation of a volatile anesthetic and its implications for the management of VSUs.

Indexed as

AnalgesiaPainSevofluraneVenous InsufficiencyVenous Stasis UlcerWound Management

Identifiers

PMID34221949
PMCPMC8241821
OpenAlexW3129406266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.